

RÉSUMÉ DIGEST

Act 956 (SB 43)

2026 Regular Session

McMath

New law establishes the Psychedelic-Assisted Therapy Initiative within the La. Dept. of Health, office of behavioral health.

New law establishes the following purposes of the initiative:

- (1) To identify academic health centers that are conducting clinical studies and clinical trial-enabling studies for the use of psychedelic-assisted therapy for the treatment of opioid use disorders, co-occurring substance use disorders, and treatment-resistant neurological or mental health conditions.
- (2) To utilize the human service districts and authorities to identify eligible participants.
- (3) To provide information to allow parishes utilizing opioid settlement funds to enroll eligible patients residing in the parish to participate in the studies or to support clinical trial-enabling studies.
- (4) To designate a state point of contact to coordinate with federal agencies and other states with regard to psychedelic assisted therapy and related drug development.

New law authorizes the department to seek and receive federal funds, gifts, grants, and donations for the program in addition to utilizing opioid settlement funds.

New law requires participating academic health centers to submit an annual progress report to the department and requires the department to submit a compiled report to the legislature by March first of each year.

New law requires the participating academic health centers to coordinate with other states that are conducting clinical trials for the use of psychedelic-assisted therapy to the extent feasible.

New law authorizes academic health centers to enter into agreements with drug developers to establish a consortium for purposes of conducting drug development clinical trials with ibogaine and psychedelic medication treatments and provides for the process to establish a consortium.

New law provides for the distribution of any revenue attributable to newly developed intellectual property rights and other commercial rights arising from a drug development clinical trial, including that not less than two and one half percent of net sales running royalty to the state.

Effective August 1, 2026.

(Adds R.S. 28:211 and 212)